BACKGROUND: Stenting for symptomatic intracranial atherosclerotic disease is a therapeutic option in patients in whom medical therapy fails. OBJECTIVE: To determine the periprocedural complication rates and mid-term restenosis rates in patients treated with balloon-expandable stents (BESs) compared with selfexpanding stents (SESs). METHODS: A retrospective review of consecutive patients treated with intracranial stents at 5 institutions was performed. Predictors of 30-day stroke and death as well as mid-term restenosis rates were analyzed. RESULTS: A total of 670 lesions were treated in 637 patients with a mean age of 57 6 13 years. A total of 454 lesions (68%) were treated with BESs and 216 lesions (32%) with SESs. The overall 30-day periprocedural complication rate was 6.1%, without any difference noted between the 2 groups. Patients treated within 24 hours of the index event were significantly more likely to have experienced a periprocedural complication (odds ratio [OR], 4.0; 95% confidence interval [CI]: 1.7-6.7; P , .007), whereas focal lesions were less likely to have a complication (OR, 0.31; 95% CI: 0.13-0.72; P , .001). Midterm restenosis was less likely in patients with a lower percentage of posttreatment stenosis (OR, 0.97; 95% CI: 0.95-0.99; P , .006), which was more common in BES-treated patients and focal concentric lesions (OR, 0.33; 95% CI: 0.23-0.55; P , .0001). CONCLUSION: BESs have periprocedural complication rates similar to those of SESs. Less posttreatment stenosis was associated with lower rates of mid-term restenosis. Future randomized trials comparing BESs and SESs may help to identify the stent type that is safest and most durable.
I
ntracranial atherosclerotic disease (ICAD) has been implicated as the etiology of ischemic stroke in 10% of patients in the United States and in as many as 33% in China. 1, 2 Recent studies have shown that patients with symptomatic lesions with more than 70% luminal narrowing and with the event occurring within 2 weeks appear to have a 23% risk of subsequent events at 1 year despite receiving adequate antiplatelet or anticoagulation therapy. 3 Endovascular treatments offer potential treatment strategies for patients with symptomatic ICAD. Balloon angioplasty offers a deliverable technology with lower cost, but with the potential for plaque dissection and vessel recoil leading to restenosis. 4, 5 Bare metal balloon-expandable stents (BESs) have been used but may be difficult to deliver through the carotid siphon because of the stiffness of the catheter. With recent advances in guide catheter technology, deliverability has improved for BESs. These stents allow for increase in luminal gain compared with angioplasty alone or self-expanding stents (SESs) and thus may be associated with lower restenosis rates. 6 Drug-eluting BESs have a deliverability profile similar to that of bare metal stents and may offer lower rates of restenosis, 7 but reports from the coronary vessels do suggest concerns for delayed thrombosis, particularly with premature discontinuation of clopidogrel and in patients with diabetes. 8 The Wingspan stent (Boston Scientific, Natick, Massachusetts) is an SES that is flexible and allows for a high rate of delivery to the target lesion. 9 However, there have been concerns with regard to restenosis and the clinical consequences associated with this device. 10 Given the varied experiences reported in the literature, we sought to compare periprocedural complications and restenosis differences in patients treated with BESs and SESs in high-volume centers that perform these procedures.
PATIENTS AND METHODS
This is a study of intracranial stenting culled from 5 Patients who presented with acute arterial occlusion treated with stents were excluded. Additionally, patients treated with primary intent for angioplasty alone (ie, not stent failures) were not included in this study.
Data were collected with regard to demographics, clinical history, type of stent used, periprocedural complications, timing of treatment, radiographic studies performed, type of treatment used, treatment failures, and follow-up imaging to assess for restenosis. The following types and number of BESs were deployed: Vision (N = 94), Mini-Vision (N = 165), Penta (N = 12) (Abbott Vascular, Abbott Park, Illinois), Taxus, Express 2 (N = 20) (Boston Scientific), Cypher (N = 3) (Cordis Corporation, Miami Lakes, Florida), S70 (N = 30), Driver (N = 94) (Medtronic, Santa Rosa, California), Apollo (N = 29) (MicroPort Medical, Shanghai, China), and BiodivYsio (N = 7) (Biocompatibles, San Jose, California). The Wingspan stent (Boston Scientific) was the only SES used. Angiograms were reviewed to determine the lesion type based on the previously described Mori classification, 11 stenosis before treatment, and stenosis after treatment blinded to the clinical history. Severity of stenosis was measured using the formula {[1 2 (D stenosis / D normal )]} 3 100, as previously described.
12 D stenosis was defined as the diameter of the maximum stenosis and D normal as the vessel diameter of a straight segment proximal to the stenosis.
Different institutional protocols were used to assess for restenosis in follow-up imaging. If transcranial Doppler (TCD) was used, each patient underwent ultrasonography before treatment, the day after treatment, and then at 3 and 6 months. The following values were considered significant for restenosis based on TCD criteria: a mean velocity of greater than 160 cm/s in the middle cerebral artery, greater than 120 cm/s in the internal carotid artery, and greater than 100 cm/s for the basilar or vertebral artery. Additionally, the TCD velocities were compared with the pretreatment and posttreatment values. If TCD velocities showed progression on follow-up studies or if clinical symptoms correlating with the ipsilateral side developed in the patient, catheter angiography was performed to confirm the degree of narrowing. When computed tomography angiography was used, if the entire stented segment and proximal and distal portions were visualized without evidence of narrowing, patients were designated as exhibiting no evidence of restenosis. If there was poor visualization of the stented segment or the distal portion appeared tapered, a catheter angiogram was obtained to better define the degree of narrowing. When catheter angiography was used, the method described for pretreatment angiography was used. If the narrowing was greater than 50%, this was considered a restenosis. We analyzed patients who had studies within the 3-to 6-month time frame to assess for mid-term restenosis.
Procedure
All patients were pretreated with aspirin and either ticlopidine or clopidogrel for at least 3 days before the procedure. If the procedure was emergent, then a loading dose of clopidogrel was given based on institutional protocol, but a minimum of 450 mg was administered if the procedure was to be done within 4 hours. The patients were placed under general anesthesia or conscious sedation based on institutional protocol. A 6-French guide catheter was placed in the ipsilateral target vessel to access the intracranial lesion. In patients with more tortuous anatomy, a long sheath was placed in conjunction with the guide catheter. All patients were given systemic intravenous heparin to achieve an activated clotting time of 225 to 300 seconds during the procedure. A microcatheter and microwire were used to traverse the lesion under roadmapping guidance. The microcatheter was removed over an exchange length .014-inch microwire. For SES placement, a balloon was navigated over the microwire and placed across the stenosis. The balloon was also inflated slowly over 30 to 60 seconds to nominal pressure to 10% less than the measured luminal diameter. An SES was placed over the microwire and deployed across the lesion with at least 2 mm of the stent on each side of the lesion covering normal segments of the vessel. If a BES was placed, this was navigated over the microwire and positioned across the lesion with inflation over 30 to 60 seconds to nominal pressure. The stent was sized to 10% less than the measured luminal diameter. After stent deployment, the blood pressure was reduced to less than 130/80 mm Hg, and the patients were monitored over a 24-hour period. If any neurologic change occurred, appropriate imaging was performed with computed tomography or magnetic resonance imaging scans of the brain. Patients were maintained on dual antiplatelet therapy (aspirin and either ticlopidine or clopidogrel) for at least 3 months postprocedure.
Statistics
A univariate analysis was performed using the Fisher exact test for categorical variables and the Student t test for continuous variables to compare SESs and BESs. A similar univariate analysis was then performed to determine predictors of periprocedural stroke and mid-term restenosis. A binary logistic regression was then constructed with variables with a P value ,.20 to determine independent associations with the use of BESs, periprocedural stroke, and mid-term restenosis in follow-up imaging. Analysis was performed using SPSS version 10.0 (SPSS Inc, Chicago, Illinois).
RESULTS
A total of 670 lesions were treated in 637 patients with a mean age of 57 6 13 years, of whom 222 (32%) were women. The distribution of stent placement was as follows: middle cerebral artery, 270 (40%); posterior circulation, 263 (39%); and intracranial internal carotid artery, 137 (21%). The ethnic distribution was as follows: white, 323 (48%); Asian, 269 (40%); African American, 71 (11%); and Hispanic, 7 (1%). A total of 454 lesions (68%) were treated with BESs and 216 lesions (32%) with SESs. Of the BESs implanted, 23 (5%) were drug-eluting stents. Table 1 summarizes the univariate analysis comparing SESs with BESs. Mori A lesions were more frequent in the SES group, and postprocedure residual stenosis was lower in the BES group. In binary logistic regression modeling, the use of BESs was associated with a significantly lower percentage of stenosis after the procedure (odds ratio [OR], 0.91; 95% confidence interval [CI]: 0.89-0.93; P , .0001), whereas Mori A lesions were more common in the SES group (OR, 1.95; 95% CI: 1.31-2.88; P , .001).
There were an additional 38 lesions in which a stent could not be delivered, and these patients were not included in the analysis because the patients were either treated with angioplasty alone or medical therapy. A BES could not be placed in 35 lesions and an SES could not be placed in 3 lesions. Thus, the technical failure rate for delivery of a BES was 35 of 489 lesions (7.1%) and 3 of 219 lesions (1.4%) for an SES (P , .001).
The 30-day periprocedural stroke or death resulted in 41 procedures (6.1%), with 31 ischemic strokes, and 8 hemorrhagic strokes, and 2 deaths not related to the stroke complication (aspiration pneumonia and sepsis). There were an additional 4 deaths caused by the complications of the periprocedural stroke; thus, a total of 6 patients (0.94%) died. Of the 31 ischemic strokes, perforator strokes occurred in 20 procedures (2.98%), whereas distal embolic strokes occurred in 11 procedures (1.64%). The majority of complications occurred within the first 24 hours of the procedure (n = 35, 5.2%). There was no difference in periprocedural stroke complications between the BES group and SES group (6.0% vs 6.4%, respectively). Only 1 procedure (4.3%) with a drug-eluting stent resulted in a periprocedural complication. Table 2 summarizes the univariate predictors of 30-day stroke and death in patients successfully treated with stents. Patients treated urgently or acutely with a complex lesion (Mori B or C) involving the middle cerebral artery and a higher percentage of stenosis pretreatment appeared to have a higher risk of stroke. In contrast, ischemic or hemorrhagic stroke complications were less likely to develop in patients with intracranial internal carotid artery lesions. In binary logistic regression modeling, patients treated within 24 hours were at significantly higher risk of periprocedural stroke or death (OR, 4.0; 95% CI: 1.7-6.7; P , .001), whereas Mori type A lesions were safer to treat (OR, 0.31; 95% CI: 0.13-0.72; P , .007).
Follow-up imaging performed between 3 and 6 months (midterm) to assess for restenosis was available for 485 stents (72%). Drug-eluting stents were not analyzed for overall restenosis, but of the 23 placed, only 2 (8.6%) showed mid-term restenosis. A total of 54 (11%) patients presented with a transient ischemic attack (TIA) or stroke when the mid-term restenosis was detected. The method of imaging used to detect restenosis was catheter angiography in 334 patients (69%), computed tomography angiography in 43 patients (9%), and TCD in 108 patients (22%). Overall, patients with a BES had a significantly lower restenosis rate at 20% (60 of 295 lesions) compared with 28% (53 of 190 lesions) for SES (P , .02). When comparing patients assessed with catheter angiography for restenosis, BESs were noted to have 20% (47 of 230) compared with 30% (31 of 104) for SESs (P , .01). The mean stenosis posttreatment with SESs was 24 6 11% compared with 12 6 11% (P , .01) for BESs. Table 3 summarizes the predictors of restenosis after stent implantation. In patients with lower posttreatment stenosis and Mori A lesions, restenosis was less likely to develop. The use of a BES had a significant interaction with posttreatment stenosis and thus was not included in the multivariate model for prediction of restenosis. Patients in whom a BES was implanted were more likely to have a lower stenosis posttreatment, which correlated with lower restenosis rates. Table 4 summarizes the independent predictors of the development of restenosis. Patients with lower poststent stenosis were protected from restenosis, whereas patients with Mori B or C lesions were at a significantly higher risk of the development of restenosis. When comparing patients treated in China with those in the United States, there were no differences in periprocedural stroke rates (6.1% vs 6.2%, respectively) or overall restenosis rates (25% vs 22%, respectively). Moreover, when we performed an analysis to determine whether ethnicity was linked to periprocedural stroke or restenosis, no statistical differences were found.
DISCUSSION
This report demonstrates that treatment of intracranial atheromatous lesions with BESs has periprocedural complication rates similar to those of SESs. Increased luminal gain and a lower posttreatment stenosis were associated with a lower restenosis rate in the mid-term. Additionally, patients treated within 24 hours of presenting symptom onset with a Mori type B or C lesion were at a higher risk of periprocedural stroke.
The SES technology offers the advantage of easier stent delivery in the setting of tortuous intracranial anatomy. Unfortunately, there are concerns with regard to restenosis that may lead to further neurologic events and repeat procedures with their inherent complications. The proposed mechanism for this may relate to the sustained force of the stent on the artery leading to neovascularization and thus aggressive neointimal hyperplasia. 13 In a 4-center registry, the 30 day periprocedural complication rate was 6.1% for stroke or death in 82 treated lesions.
14 A follow-up study was performed by the same group of 84 patients with angiographic imaging to assess for mid-term restenosis at an average of 5.9 months. The rate of restenosis or complete thrombosis was 35%. Eight of the 29 patients (27%) with restenosis or occlusion presented with stroke or TIA. Thus, the mid-term rate of stroke or TIA was noted to be nearly 16% in patients treated with the Wingspan stent system. 10 Moreover, 15 of the 29 patients underwent repeat treatment with angioplasty or stenting, and reperfusion hemorrhage developed in 1 patient. 10 Similarly, the National Institutes of Health registry of 129 patients showed a 14% rate of stroke or death before 30 days or ipsilateral stroke at 6 months. 15 Although SESs are promising with regard to deliverability, there is concern about restenosis because it does not appear to be a benign entity based on these studies. Our current study highlights that 11% of patients with restenosis presented with neurologic symptoms. Additionally, the current study shows that although there was a higher rate of the inability to deliver a BES, the restenosis rates were lower in patients in whom a BES was successfully placed.
There have been concerns about the use of BESs because of the risk of stroke from the procedure as well as the difficulty with navigability. A recent systematic review assessed 31 studies in the literature with reports of intracranial stenting. 6 A total of 906 patients were treated with BESs and 271 with SESs. There was no statistical difference in periprocedural complications between the BES and SES groups (9.5% vs 7.7%, respectively), but the posttreatment residual stenosis was significantly lower in the BES group (11% vs 29%). Additionally, there was a significantly higher proportion of patients with restenosis in the SES group compared with the BES-treated patients. 6 Our current study confirms similar periprocedural complication rates between BES and SES, although BES is associated with a lower midterm restenosis rate.
The Mori classification has been proposed as a method of assessing plaque characteristics before treatment with a stent. Mori A lesions are concentric and less than 5 mm in length, whereas type B lesions are eccentric lesions 5 to 10 mm in length, and type C lesions are longer than 10 mm with excessive tortuosity associated with them. 11 We did not include any patients with total occlusions in our study. The association of higher complication rates with the type of lesion is important for operators to recognize. This is likely attributed to the fact that longer lesions are more likely to span perforator branches that may be occluded at the time of stent placement. Moreover, eccentric lesions may be more friable, and distal embolization may occur with this type of lesion. Also, eccentric lesions may be more prone to vessel dissection or perforation with angioplasty. Mori B and C lesions are also longer, and placement of a stent across longer lesions has been correlated with in-stent restenosis in the coronary arteries. 16 The current study assessed angiographic high-risk features, but future trials may assess the technique of spin-echo magnetic resonance imaging 17 with contrast or intravascular ultrasound. 18 These techniques may help to assess the vulnerability of a plaque and features that may deem the lesion to be at higher risk to treat.
Patients treated within 24 hours of their stroke or TIA were more likely to have a periprocedural complication. These patients were treated because of crescendo TIAs or progression of their clinical symptoms, and they also represent a more clinically unstable group of patients to treat medically. Previous studies have confirmed that endovascular treatment closer to the index event is associated with higher rates of periprocedural strokes. 19, 20 Moreover, placement of a stent in a coronary vessel in the acute setting is associated with poor vessel healing and higher levels of fibrin deposition and inflammation, leading to more thrombotic complications as well as restenosis. 21 The highest rate of recurrence also appears to occur within the first 2 weeks of the index event, 3 thus making the clinical decision regarding treatment selection difficult. A second mechanism may be related to the dosing and timing of administration of clopidogrel relative to stent implantation. A loading dose of 600 mg has been shown to enhance platelet inhibition compared with 300 mg within 4 hours of stent implantation in the coronary arteries. There is a limit to oral absorption, and thus doses greater than 600 mg may not yield additional inhibition. 22 Each center administered 450 mg or more of clopidogrel when performing an emergent stent placement, but unfortunately we do not have precise timing of dosing, and, thus, this may represent a possible explanation for higher stroke rates in patients treated emergently.
There are several limitations to the current study because of its retrospective design. The first limitation is that there were different methodologies used for detecting restenosis based on institutional protocols, and a significant proportion of patients did not undergo follow-up imaging. Additionally, there were imbalances, with fewer available follow-up data for BES-treated patients. The SONIA (Stroke Outcomes and Neuroimaging of Intracranial Atherosclerosis) trial showed that TCD has a good negative predictive value for detecting a moderate to severe stenosis in intracranial atherosclerosis. 23 We used the thresholds for TCD from this study, but it is possible that we underestimated the restenosis rates by not performing catheter angiography on each patient. Patients in whom TCD was performed were followed sequentially for changes in mean flow velocities compared with baseline. A second potential limitation is that the cohorts were from different time periods in which these patients were treated in centers in the United States and China. It is not likely that there have been significant improvements in techniques leading to differences in periprocedural complications given that the results are similar to those of other published studies conducted during similar time frames. A third limitation is that images were not reviewed by a central core laboratory because of the retrospective nature of the study. Last, we do not have consistent longer term follow-up data with which to determine the durability of the treatment. Nonetheless, the study offers insight into the complication rates and mid-term restenosis rates associated with both stent platforms. Stent design may affect clinical outcomes in the future and should be addressed in future ongoing prospective clinical trials.
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